Abstract
CD133 and aldehyde dehydrogenase 1 (ALDH1) expression are reliable poor-prognosis markers associated with the presence of adverse biomarkers and subtypes of breast cancer. The aim of our study was to investigate and compare the clinical impact of CD133 and ALDH1 expression in invasive breast cancer. A total of 291 consecutive patients with invasive breast cancer who underwent breast cancer operations from 2005 to 2010 at a single institution were included in this retrospective review. CD133 and ALDH1 expression were determined by immunohistochemistry. CD133 and ALDH1 expression were positive in 24.7% and 22.0% of the patients, respectively, and were associated with tumor size, cancer stage, estrogen receptor negativity, nonluminal subtype, triple-negative breast cancer, and recurrence. CD133 expression was significantly associated with lymph node metastasis, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, chemotherapy, and poor disease-free (p=0.002) and overall survival (p=0.014), but ALDH1 expression was not. Cancer stage (p<0.001) was an independent prognostic factor for disease-free survival in multivariate analysis. Cancer stage (p<0.001) and receipt of radiotherapy (p=0.045) were ind...Continue Reading
References
Jan 10, 2008·Journal of Cellular and Molecular Medicine·A K Croker, A L Allan
Mar 29, 2008·Cell Stem Cell·Christophe GinestierGabriela Dontu
May 20, 2008·Journal of Clinical Laboratory Analysis·Wojciech JelskiMaciej Szmitkowski
Sep 12, 2008·Nature Reviews. Cancer·Jane E Visvader, Geoffrey J Lindeman
Mar 3, 2009·Surgical Oncology·Suebwong ChuthapisithOleg Eremin
Apr 8, 2009·Breast Cancer Research and Treatment·Wonshik HanUNKNOWN Korean Breast Cancer Society
Apr 24, 2009·Cancer Science·Koji MorimotoShinzaburo Noguchi
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomonori TaneiShinzaburo Noguchi
Nov 17, 2009·Breast Cancer Research and Treatment·Erika ResetkovaSunil Badve
Feb 1, 2011·Cancer Science·Po ZhaoXiaoying Li
Jul 16, 2011·Pathology, Research and Practice·G GiuffrèG Tuccari
Oct 22, 2011·Histopathology·Yasuyo OhiAkihide Tanimoto
Dec 20, 2011·Cancer·Masahiro SakakibaraMasaru Miyazaki
Feb 11, 2012·Journal of breast cancer·Im-Kyung KimByeong-Woo Park
Oct 11, 2012·PloS One·Naoki AomatsuKosei Hirakawa
Oct 12, 2012·Breast Cancer Research and Treatment·Julia Y S TsangGary M Tse
Nov 7, 2012·Clinical Breast Cancer·Sudeshna GangopadhyayAshis Mukhopadhyay
May 11, 2013·International Journal of Cancer. Journal International Du Cancer·Rosa NadalM Jose Serrano
Citations
Apr 12, 2016·Journal of breast cancer·Antonio Ieni, Giovanni Tuccari
Oct 11, 2016·Journal of breast cancer·Christine A Fargeas, Denis Corbeil
Jan 5, 2017·Oncotarget·Abhilasha SinhaWael M ElShamy
Mar 23, 2017·Scientific Reports·Hansol BaeSun Jung Kim
Jun 24, 2020·BMC Cancer·Yu SongQiang Sun
Jun 24, 2017·Medicine·Juan YaoQi-Chao Ni
Aug 11, 2018·Current Stem Cell Research & Therapy·Iván Flores-RamírezElizabeth Langley
Apr 13, 2017·Breast Cancer Research : BCR·Iole CordoneAndrea Pace
May 12, 2020·Cancer Biomarkers : Section a of Disease Markers·Ting Ting LiuJu Lun Yang
Nov 28, 2018·Cell Death & Disease·Yanyan LiYuquan Wei
Aug 5, 2019·Molecular Aspects of Medicine·Luis Enrique Cortés-HernándezCatherine Alix-Panabières
Jan 19, 2021·Annals of Diagnostic Pathology·Eric GyanWilliam Owiredu